Cytokines and Inflammation in Meniere Disease

키워드

참고문헌 (124)

1. Amanat S, "A systematic review of extreme phenotype strategies to search for rare variants in genetic studies of complex disorders", Genes(Basel), 11(9), pp.987~ (2020)
2. Espinosa-Sanchez JM, "Meniere’s disease", Handb Clin Neurol, 137, pp.257~277 (2016)
3. Stahle J, "Long-term progression of Meniere’s disease", Acta Otolaryngol Suppl, 485, pp.78~83 (1991)
4. Lopez-Escamez JA, "Diagnostic criteria for Meniere’s disease", J Vestib Res, 25(1), pp.1~7 (2015)
5. Frejo L, "Clinical subgroups in bilateral Meniere disease", Front Neurol, 7, pp.182~ (2016)
6. Frejo L, "Extended phenotype and clinical subgroups in unilateral Meniere disease : a cross-sectional study with cluster analysis", Clin Otolaryngol, 42(6), pp.1172~1180 (2017)
7. Requena T, "Familial clustering and genetic heterogeneity in Meniere’s disease", Clin Genet, 85(3), pp.245~252 (2014)
8. Lee JM, "Genetic aspects and clinical characteristics of familial Meniere’s disease in a South Korean population", Laryngoscope, 125(9), pp.2175~2180 (2015)
9. Roman-Naranjo P, "Genetics of vestibular syndromes", Curr Opin Neurol, 31(1), pp.105~110 (2018)
10. Birgerson L, "Familial Meniere’s disease : a genetic investigation", Am J Otol, 8(4), pp.323~326 (1987)
11. Klar J, "A Meniere’s disease gene linked to chromosome 12p12.3", Am J Med Genet B Neuropsychiatr Genet, 141(5), pp.463~467 (2006)
12. Morrison AW, "Familial Meniere’s disease : clinical and genetic aspects", J Laryngol Otol, 123(1), pp.29~37 (2009)
13. Oliveira CA, "Occurrence of familial Meniere’s syndrome and migraine in Brasilia", Ann Otol Rhinol Laryngol, 111(3 Pt 1), pp.229~236 (2002)
14. Arweiler-Harbeck D, "Genetic aspects of familial Meniere’s disease", Otol Neurotol, 32(4), pp.695~700 (2011)
15. Hietikko E, "A replication study on proposed candidate genes in Meniere’s disease, and a review of the current status of genetic studies", Int J Audiol, 51(11), pp.841~845 (2012)
16. Roman-Naranjo P, "Burden of rare variants in the OTOG gene in familial Meniere’s disease", Ear Hear, 41(6), pp.1598~1605 (2020)
17. Sajjadi H, "Meniere’s disease", Lancet, 372(9636), pp.406~414 (2008)
18. Paparella MM, "Etiology, pathophysiology of symptoms, and pathogenesis of Meniere’s disease", Otolaryngol Clin North Am, 35(3), pp.529~545 (2002)
19. Greco A, "Meniere’s disease might be an autoimmune condition?", Autoimmun Rev, 11(10), pp.731~738 (2012)
20. Kim SH, "Autoimmunity as a candidate for the etiopathogenesis of Meniere’s disease : detection of autoimmune reactions and diagnostic biomarker candidate", PLoS One, 9(10), pp.e111039~ (2014)
21. Joannovic D, "Zur Wirkung fermentativ gewonner spaltungsprodukte aus Geweben und Bakterien", Wein Klin Wschr, 70, pp.1410~1411 (1920)
22. Masugi M, "Uber die spezifisch zytotoxischen Veranderungen der Niere und sehr Leber durch das spezifische Antiserum(Nephrotoxin und Hepatoxin)", Trans Jap Pathol, 21, pp.329~341 (1931)
23. Lehnhardt E, "Pathogenesis of sudden hearing disorders", Dtsch Gesundheitsw, 13(4), pp.105~109 (1958)
24. Kikuchi M, "On the “sympathetic otitis”", Zibi Rinsyo Kyoto, 52, pp.600~ (1959)
25. Beickert P, "On the problem of perception deafness and autoallergy", Z Laryngol Rhinol Otol, 40, pp.837~842 (1961)
26. Yoshihiko T, "Studies on experimental allergic(isoimmune)labyrinthitis in guinea pigs", Acta Otolaryngol, 58, pp.49~64 (1964)
27. McCabe BF, "Autoimmune sensorineural hearing loss", Ann Otol Rhinol Laryngol, 88(5 Pt 1), pp.585~589 (1979)
28. Verdoodt D, "On the pathophysiology of DFNA9 : effect of pathogenic variants in the COCH gene on inner ear functioning in human and transgenic mice", Hear Res, 401, pp.108162~ (2021)
29. Baruah P., "Cochlin in autoimmune inner ear disease: is the search for an inner ear autoantigen over?", Auris Nasus Larynx, 41(6), pp.499~501 (2014)
30. Danial-Farran N, "Homozygote loss-of-function variants in the human COCH gene underlie hearing loss", Eur J Hum Genet, 29(2), pp.338~342 (2021)
31. Jung J, "Cleaved cochlin sequesters pseudomonas aeruginosa and activates innate immunity in the inner ear", Cell Host Microbe, 25(4), pp.513~525 (2019)
32. Hughes GB, "Autoimmune reactivity in Meniere’s disease : a preliminary report", Laryngoscope, 93(4), pp.410~417 (1983)
33. Tyrrell JS, "Prevalence, associated factors, and comorbid conditions for Meniere’s disease", Ear Hear, 35(4), pp.e162~e169 (2014)
34. Hietikko E, "High incidence of Meniere-like symptoms in relatives of Meniere patients in the areas of Oulu University Hospital and Kainuu Central Hospital in Finland", Eur J Med Genet, 56(6), pp.279~285 (2013)
35. Gazquez I, "High prevalence of systemic autoimmune diseases in patients with Meniere’s disease", PLoS One, 6(10), pp.e26759~ (2011)
36. Bovo R, "Vertigo and autoimmunity", Eur Arch Otorhinolaryngol, 267(1), pp.13~19 (2010)
37. Chiarella G, "A proteomics-driven assay defines specific plasma protein signatures in different stages of Meniere’s disease", J Cell Biochem, 115(6), pp.1097~1100 (2014)
38. Lopez-Escamez JA, "Polymorphisms of CD16A and CD32 Fcγ receptors and circulating immune complexes in Meniere’s disease : a case-control study", BMC Med Genet, 12, pp.2~ (2011)
39. Gloddek B, "Clinical and experimental studies of autoimmune inner ear disease", Acta Otolaryngol Suppl, (548), pp.10~14 (2002)
40. Yoo TJ, "Type II collagen-induced autoimmune endolymphatic hydrops in guinea pig", Science, 222(4619), pp.65~67 (1983)
41. Yoo TJ, "Etiopathogenesis of Meniere’s disease : a hypothesis", Ann Otol Rhinol Laryngol Suppl, 113, pp.6~12 (1984)
42. Brookes GB, "Circulating immune complexes in Meniere’s disease", Arch Otolaryngol Head Neck Surg, 112(5), pp.536~540 (1986)
43. Yoo TJ, "Presence of autoantibodies in the sera of Meniere’s disease", Ann Otol Rhinol Laryngol, 110(5 Pt 1), pp.425~429 (2001)
44. Bernstein JM, "Further observations on the role of the MHC genes and certain hearing disorders", Acta Otolaryngol, 116(5), pp.666~671 (1996)
45. Gazquez I, "MICA-STR A.4 is associated with slower hearing loss progression in patients with Meniere’s disease", Otol Neurotol, 33(2), pp.223~229 (2012)
46. Requena T, "Allelic variants in TLR10 gene may influence bilateral affectation and clinical course of Meniere’s disease", Immunogenetics, 65(5), pp.345~355 (2013)
47. Cabrera S, "Intronic variants in the NFKB1 gene may influence hearing forecast in patients with unilateral sensorineural hearing loss in Meniere’s disease", PLoS One, 9(11), pp.e112171~ (2014)
48. Frejo L, "Regulation of Fn14 receptor and NF-κB underlies inflammation in Meniere’s disease", Front Immunol, 8, pp.1739~ (2017)
49. Xu WD, "Role of the TWEAK", Fn14 pathway in autoimmune diseases, 2016, pp.64(1), 44~50
50. Rask-Andersen H, "Lymphocyte-macrophage activity in the human endolymphatic sac", Acta Otolaryngol Suppl, 485, pp.15~17 (1991)
51. Okano T, "Distribution of bone marrow-derived cells in the vestibular end organs and the endolymphatic sac", Acta Otolaryngol Suppl, (563), pp.88~94 (2010)
52. Moller MN, "Gene expression in the human endolymphatic sac : the solute carrier molecules in endolymphatic fluid homeostasis", Otol Neurotol, 36(5), pp.915~922 (2015)
53. Moller MN, "Expression of histamine receptors in the human endolymphatic sac : the molecular rationale for betahistine use in Menieres disease", Eur Arch Otorhinolaryngol, 273(7), pp.1705~1710 (2016)
54. Hu BH, "Immune cells and non-immune cells with immune function in mammalian cochleae", Hear Res, 362, pp.14~24 (2018)
55. O’Malley JT, "Anti CD163+, Iba1+, and CD68+ cells in the adult human inner ear : normal distribution of an unappreciated class of macrophages", microglia and implications for inflammatory otopathology in humans, 2016, pp.37(1), 99~108
56. Liu W, "Macrophages in the human cochlea : saviors or predators : a study using super-resolution immunohistochemistry", Front Immunol, 9, pp.223~ (2018)
57. Kampfe Nordstrom C, "The human endolymphatic sac and inner ear immunity : macrophage interaction and molecular expression", Front Immunol, 9, pp.3181~ (2019)
58. Moller MN, "Gene expression demonstrates an immunological capacity of the human endolymphatic sac", Laryngoscope, 125(8), pp.E269~E275 (2015)
59. Broderick L, "Hereditary autoinflammatory disorders : recognition and treatment", Immunol Allergy Clin North Am, 39(1), pp.13~29 (2019)
60. Martinez-Quiles N, "Updates on autoinflammatory diseases", Curr Opin Immunol, 55, pp.97~105 (2018)
61. Adams JC, "Selective activation of nuclear factor kappa B in the cochlea by sensory and inflammatory stress", Neuroscience, 160(2), pp.530~539 (2009)
62. Nie H, "Phosphorylation of FOXP3 controls regulatory T cell function and is inhibited by TNF-α in rheumatoid arthritis", Nat Med, 19(3), pp.322~328 (2013)
63. Ren J, "The determinations of tumor necrosis factor and interleukin 6 in serum of patients with sudden sensorineural hearing loss", Lin Chuang Er Bi Yan Hou Ke Za Zhi, 12(7), pp.311~313 (1998)
64. Rahman MU, "Etanercept therapy for immune-mediated cochleovestibular disorders : preliminary results in a pilot study", Otol Neurotol, 22(5), pp.619~624 (2001)
65. Keithley EM, "Tumor necrosis factor alpha can induce recruitment of inflammatory cells to the cochlea", Otol Neurotol, 29(6), pp.854~859 (2008)
66. Wang X, "Blockage of immune-mediated inner ear damage by etanercept", Otol Neurotol, 24(1), pp.52~57 (2003)
67. Lobo D, "TNFalpha blockers do not improve the hearing recovery obtained with glucocorticoid therapy in an autoimmune experimental labyrinthitis", Eur Arch Otorhinolaryngol, 263(7), pp.622~626 (2006)
68. Kassner SS, "Proinflammatory and proadhesive activation of lymphocytes and macrophages in sudden sensorineural hearing loss", Audiol Neurootol, 16(4), pp.254~262 (2011)
69. Suslu N, "Utility of immunologic parameters in the evaluation of Meniere’s disease", Acta Otolaryngol, 129(11), pp.1160~1165 (2009)
70. Svrakic M, "Diagnostic and prognostic utility of measuring tumor necrosis factor in the peripheral circulation of patients with immune-mediated sensorineural hearing loss", Arch Otolaryngol Head Neck Surg, 138(11), pp.1052~1058 (2012)
71. Pathak S, "N-Acetylcysteine attenuates tumor necrosis factor alpha levels in autoimmune inner ear disease patients", Immunol Res, 63(1-3), pp.236~245 (2015)
72. Blesa S, "Oral N-acetylcysteine attenuates the rat pulmonary inflammatory response to antigen", Eur Respir J, 21(3), pp.394~400 (2003)
73. Angeli SI, "L-N-Acetylcysteine treatment is associated with improved hearing outcome in sudden idiopathic sensorineural hearing loss", Acta Otolaryngol, 132(4), pp.369~376 (2012)
74. Thornberry NA, "A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes", Nature, 356(6372), pp.768~774 (1992)
75. Zheng D, "Inflammasome activation and regulation : toward a better understanding of complex mechanisms", Cell Discov, 6, pp.36~ (2020)
76. Andrei C, "Phospholipases C and A2 control lysosome-mediated IL-1 beta secretion : implications for inflammatory processes", Proc Natl Acad Sci U S A, 101(26), pp.9745~9750 (2004)
77. Sims JE, "The IL-1 family : regulators of immunity", Nat Rev Immunol, 10(2), pp.89~102 (2010)
78. Pathak S, "Autoimmune inner ear disease patient-associated 28-kDa proinflammatory IL-1β fragment results from caspase-7-mediated cleavage in vitro", JCI Insight, 5(3), pp.e130845~ (2020)
79. Mandrup-Poulsen T, "Blockade of interleukin 1 in type 1 diabetes mellitus", Nat Rev Endocrinol, 6(3), pp.158~166 (2010)
80. Arend WP., "Cytokine imbalance in the pathogenesis of rheumatoid arthritis: the role of interleukin-1 receptor antagonist", Semin Arthritis Rheum, 30(5 Suppl 2), pp.1~6 (2001)
81. Luheshi NM, "Dual functionality of interleukin-1 family cytokines : implications for anti-interleukin-1 therapy", Br J Pharmacol, 157(8), pp.1318~1329 (2009)
82. Ligumsky M, "Role of interleukin 1 in inflammatory bowel disease : enhanced production during active disease", Gut, 31(6), pp.686~689 (1990)
83. Gosselin D, "Role of IL-1 and TNF in the brain: twenty years of progress on a Dr. Jekyll", Mr. Hyde duality of the innate immune system, 2007, pp.21(3), 281~289
84. Hawkins PN, "Interleukin-1-receptor antagonist in the Muckle-Wells syndrome", N Engl J Med, 348(25), pp.2583~2584 (2003)
85. Hull KM, "The expanding spectrum of systemic autoinflammatory disorders and their rheumatic manifestations", Curr Opin Rheumatol, 15(1), pp.61~69 (2003)
86. Pathak S, "IL-1β is overexpressed and aberrantly regulated in corticosteroid nonresponders with autoimmune inner ear disease", J Immunol, 186(3), pp.1870~1879 (2011)
87. Nakanishi H, "NLRP3 mutation and cochlear autoinflammation cause syndromic and nonsyndromic hearing loss DFNA34 responsive to anakinra therapy", Proc Natl Acad Sci U S A, 114(37), pp.E7766~E7775 (2017)
88. Gattorno M, "Beyond the NLRP3 inflammasome : autoinflammatory diseases reach adolescence", Arthritis Rheum, 65(5), pp.1137~1147 (2013)
89. Agostini L, "NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder", Immunity, 20(3), pp.319~325 (2004)
90. Stojanov S, "Familial autoinflammatory diseases : genetics, pathogenesis and treatment", Curr Opin Rheumatol, 17(5), pp.586~599 (2005)
91. Gattorno M, "Pattern of interleukin-1beta secretion in response to lipopolysaccharide and ATP before and after interleukin-1 blockade in patients with CIAS1 mutations", Arthritis Rheum, 56(9), pp.3138~3148 (2007)
92. Church LD, "Primer : inflammasomes and interleukin 1beta in inflammatory disorders", Nat Clin Pract Rheumatol, 4(1), pp.34~42 (2008)
93. Hashimoto S, "Innate immunity contributes to cochlear adaptive immune responses", Audiol Neurootol, 10(1), pp.35~43 (2005)
94. Henderson C, "Monogenic IL-1 mediated autoinflammatory and immunodeficiency syndromes : finding the right balance in response to danger signals", Clin Immunol, 135(2), pp.210~222 (2010)
95. Mirault T, "Recovery from deafness in a patient with Muckle-Wells syndrome treated with anakinra", Arthritis Rheum, 54(5), pp.1697~1700 (2006)
96. Mantovani A, "Tuning of innate immunity and polarized responses by decoy receptors", Int Arch Allergy Immunol, 132(2), pp.109~115 (2003)
97. Vambutas A, "Early efficacy trial of anakinra in corticosteroid-resistant autoimmune inner ear disease", J Clin Invest, 124(9), pp.4115~4122 (2014)
98. Frejo L, "Proinflammatory cytokines and response to molds in mononuclear cells of patients with Meniere disease", Sci Rep, 8(1), pp.5974~ (2018)
99. Flook M, "Differential proinflammatory signature in vestibular migraine and meniere disease", Front Immunol, 10, pp.1229~ (2019)
100. Cai T, "Characterization of the transcriptome of nascent hair cells and identification of direct targets of the Atoh1 transcription factor", J Neurosci, 35(14), pp.5870~5883 (2015)
101. Honda K, "Molecular architecture underlying fluid absorption by the developing inner ear", Elife, 6, pp.e26851~ (2017)
102. Elkon R, "RFX transcription factors are essential for hearing in mice", Nat Commun, 6, pp.8549~ (2015)
103. Hirano T, "IL-6 in inflammation, autoimmunity and cancer", Int Immunol, 33(3), pp.127~148 (2021)
104. Winkles JA, "The TWEAK-Fn14 cytokine-receptor axis : discovery, biology and therapeutic targeting", Nat Rev Drug Discov, 7(5), pp.411~425 (2008)
105. Burkly LC, "Regulation of tissue responses : the TWEAK", Fn14 pathway and other TNF, Front Immunol, pp.2015, 6[DOI]
106. Baxter FO, "IKKbeta", 2 induces TWEAK and apoptosis in mammary epithelial cells, 2006, pp.133(17), 3485~3494
107. Park JS, "TWEAK promotes osteoclastogenesis in rheumatoid arthritis", Am J Pathol, 183(3), pp.857~867 (2013)
108. Michaelson JS, "Role of TWEAK in lupus nephritis : a bench-to-bedside review", J Autoimmun, 39(3), pp.130~142 (2012)
109. Serafini B, "Expression of TWEAK and its receptor Fn14 in the multiple sclerosis brain : implications for inflammatory tissue injury", J Neuropathol Exp Neurol, 67(12), pp.1137~1148 (2008)
110. Stephan D, "TWEAK", Fn14 pathway modulates properties of a human microvascular endothelial cell model of blood brain barrier, 2013, pp.10, 9~
111. Sun SC, "Non-canonical NF-κB signaling pathway", Cell Res, 21(1), pp.71~85 (2011)
112. Ramadass V, "Small molecule NF-κB pathway inhibitors in clinic", Int J Mol Sci, 21(14), pp.5164~ (2020)
113. Gilmore TD, "Inhibitors of NF-kappaB signaling : 785 and counting", Oncogene, 25(51), pp.6887~6899 (2006)
114. Ren Z, "Resveratrol inhibits NF-kB signaling through suppression of p65 and IkappaB kinase activities", Pharmazie, 68(8), pp.689~694 (2013)
115. Crow MK, "Type I interferons in host defence and inflammatory diseases", Lupus Sci Med, 6(1), pp.e000336~ (2019)
116. Tanaka T, "IL-6 in inflammation, immunity, and disease", Cold Spring Harb Perspect Biol, 6(10), pp.a016295~ (2014)
117. Tansey MG, "The TNF superfamily in 2009: new pathways, new indications, and new drugs", Drug Discov Today, 14(23-24), pp.1082~1088 (2009)
118. Lis K, "Tumor necrosis factor inhibitors : state of knowledge", Arch Med Sci, 10(6), pp.1175~1185 (2014)
119. Smolen JS, "EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs : 2013 update", Ann Rheum Dis, 73(3), pp.492~509 (2014)
120. Dinarello CA, "Overview of the IL-1 family in innate inflammation and acquired immunity", Immunol Rev, 281(1), pp.8~27 (2018)
121. Gabay C, "IL-1 pathways in inflammation and human diseases", Nat Rev Rheumatol, 6(4), pp.232~241 (2010)
122. Ren K, "Role of interleukin-1beta during pain and inflammation", Brain Res Rev, 60(1), pp.57~64 (2009)
123. Dhimolea E, "Canakinumab", MAbs, 2(1), pp.3~13 (2010)
124. Rincon M, "Role of IL-6 in asthma and other inflammatory pulmonary diseases", Int J Biol Sci, 8(9), pp.1281~1290 (2012)

관련 논문AI추천